Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.
Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.
Although the toxicities associated with with CAR T-cell therapy receive a lot of attention, it remains the most promising therapy for relapsed leukemia, says Shah.
Shah adds that is important to understand that these toxicities are manageable, and the risk of dying from them is extremely low.
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.